Disease overview: Hairy cell leukemia (HCL) and HCL-like disorders, including HCL variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogeneous group of mature lymphoid B-cell disorders, characterized by the identification of hairy cells, a specific genetic profile, a different clinical course and the need for appropriate treatment.
point given to each of the last four markers when they are expressed and no point when they are not expressed. A score of 3 or 4 is observed in 98% of HCL cases, whereas in other HCL-like disorders, the score is usually low: 0 or 1. 5 In the international consensus guidelines, trephine bone marrow biopsy and/or aspiration has been emphasized to appreciate the tumor infiltration degree and to help diagnose complex cases (immunostaining with CD20, CD76
and Annexin A1). 6 HCL must be distinguished from HCL-V and SDRPL. HCL-V, a provisional entity 7 /L), and high beta2-microglobulin (> 2N) are associated with a poor prognosis and resistance to purine analogs (PNA). 8 In a similar manner to chronic lymphocytic leukemia (CLL), CD38 expression drives poor prognosis. 9 The immunoglobulin heavy chain variable LCH in a patient with HCL was recently described, 19 (Table 1) : A role in disease progression
In patients with refractory HCL, recurrent inactivation of the cell cycle inhibitor CDKN1B/p27 was identified in 16% of cases. 22 Additionally, KLF2 mutations were observed in 30% of marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma cases. 29 KLF2 is a transcription factor that controls the differentiation of multiple B-cell subpopulations, including marginal zone B cells. In 53 HCL patients, the two mutations most frequently identified after the BRAF mutations were histone methyltransferase KMT2C (MLL3) and CDKN1B mutations, which occur in 15% and 11% of patients, respectively. patients. 21 In HCL-V, the identification of MAP2K1 mutations is an argument that supports the diagnosis but its presence is detected in only 50% of cases. 24 These recent data highlight the genetic differences between these entities, which provides the possibility of developing novel therapeutic approaches. . 33 The use of a VE1
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antibody that is specific to BRAF-V600E mutated cells could also represent a simple and first approach in clinical practice to detect MRD. 34 
| First relapse
Patients relapsing after previous PNA treatment are more difficult to treat and are at high risk of having a significant and impaired reduced OS. 35 Therapeutic options will depend on the duration of first remission. Patients with relapse after long remission over 5 years should be re-treated with the same or an alternative PNA.
For remissions between 2 and 5 years, the use of PNA followed by rituximab, which binds to and kills CD20 positive cells by inducing apoptosis or by mediating complement and antibody dependent cytotoxicity, has been proposed. Indeed, in a prospective study including 59 untreated patients, 14 relapsed HCL patients and 7 HCL-V patients, the 5-year failure-free survival was 95%, 100% and 64% with cladribine, respectively, after which, one month later, rituximab 375 mg/m 2 was administered weekly for 8 weeks. 36 Furthermore, 59 patients (74%) achieved a negative MRD: 76% in untreated patients, 64% in relapsed patients and 71% in HCL-V patients. In a retrospective study with 41 HCL patients, we confirmed the efficacy of PNA and rituximab. 37 It is not yet known if either novel humanized, glycoengineered
Type II (obinutuzumab) 38 or the second-generation anti-CD20 monoclonal antibodies (ofatumumab) could bring benefits in terms of response.
In case of a relapse occurring before 2 years, an HCL diagnosis has to be confirmed and risk factors evaluated. 39 Patients should be considered as relapsed/refractory HCL patients. To choose the best therapeutic option, the presence of a BRAF V600E mutation must be checked. In all cases, novel therapeutic agents will depend on the BRAF mutational status. In case of mutated BRAF, specific inhibitors of the BRAF pathway should represent the best option (see below). 16, 40 In unmutated BRAF cases, depending on the accessibility of the drug and of clinical trials, immunotoxins, BCR inhibitors or a combination of bendamustine with rituximab should be considered. 
| Specific inhibitors targeting the BRAF pathway
Vemurafenib (Zelboraf) is a low-molecular-weight orally available BRAF serine-threonine kinase inhibitor and has demonstrated significant activity in patients with melanoma and subsequently in BRAF-V600E positive cancers, 15 including patients with HCL. 16, 41 The vemurafenib dose and the duration of treatment remain to be determined. These treatments are effective, with a complete response in 40% of cases.
Safety data from the clinical trials either with vemurafenib or dabrafenib include adverse (AES) and serious adverse event (SAES) skin toxicity with rash, palma-plantar hyperkeratosis, photosensibility, keratoacanthomas and cutaneous small cell carcinoma (SCC), ocular toxicity, including central serious retinopathy and retinal vein occlusion, cardiac overall response rate of 91%, including 59% with a complete response and no dose limiting toxicity. 44 The maximum tolerated dose was not established. However, capillary leak syndrome and thrombotic microangiopathy can occur and require careful monitoring.
| BCR inhibitors
Ibrutinib, a first-in-class oral inhibitor of Bruton's tyrosine kinase, is approved for treating patients with relapsed or refractory B-cell malignancies, such as CLL. 45 A multicenter phase 2 study of ibrutinib is ongoing for treatment of relapsed HCL (NCT01841723). Ibrutinib /dose with rituximab has demonstrated significant activity. 47 This regimen should also be considered in cases in which novel agents that were previously described are not available.
Oral Fludarabine at 40 mg/m 2 in combination with rituximab has also demonstrated significant activity in relapsed/refractory HCL patients previously treated with cladribine. 48 In resistant massive symptomatic splenomegaly cases with lowlevel bone marrow infiltration, splenectomy may be indicated.
| Treatments for the HCL-like disorders, HCL-V and SDRPL
There is no established consensus concerning the treatment of HCL-V.
A first-line option relies on the association of cladribine with rituximab, combined 49 or with a sequential scheme. 36 The same scheme could be followed in relapse cases. Ibrutinib could represent an alternative therapy, either at first-line or relapse. 
